首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >A potent and selective small molecule inhibitor of MCL-1 sensitizes DLBCL cell lines to the BCL-2 selective inhibitor ABT-199

【24h】

A potent and selective small molecule inhibitor of MCL-1 sensitizes DLBCL cell lines to the BCL-2 selective inhibitor ABT-199

机译：MCL-1的有效和选择性小分子抑制剂可使DLBCL细胞系对BCL-2选择性抑制剂ABT-199敏感

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2014年第6期|共1页
作者
Phillips D. C.; Xiao Y.; Lam L.; Litinovic E.; Roberts-Rapp L.; Souers A. J.; Leverson J. D.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A potent and selective small molecule inhibitor of MCL-1 sensitizes DLBCL cell lines to the BCL-2 selective inhibitor ABT-199 [J] . Phillips D. C., Xiao Y., Lam L., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第Suppla6期

机译：MCL-1的有效和选择性小分子抑制剂可使DLBCL细胞系对BCL-2选择性抑制剂ABT-199敏感
2. Anti-Leukemia Activity of the Selective BCL-2 Inhibitor ABT-199 in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By MCL-1/BCL-2 Expression Serving As Biomarker for Treatment Response [J] . Seyfried Felix, Demir Salih, Horl Rebecca, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：MCL-1 / BCL-2表达作为治疗反应的生物标志物表征了选择性BCL-2抑制剂ABT-199在儿童B细胞前体急性淋巴细胞白血病中的抗白血病活性
3. MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells [J] . Qing Wang Leukemia and lymphoma . 2019,第9a10期

机译：通过特异性抑制剂作为单一剂，可以克服对Bcl-2拮抗剂（ABT-199）的MCL-1或Bcl-XL依赖性抗性，并与ABT-199在急性髓性白血病细胞中组合
4. Virtual screening, ADMET profiling, molecular docking and dynamics approaches to search for potent selective natural molecule based inhibitors against metallothionein-III to study Alzheimer's disease [C] . Roy Sandip, Kumar Ajit, Provaznik Ivo IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：虚拟筛选，ADMET分析，分子对接和动力学方法以寻找有效的基于选择性天然分子的金属硫蛋白-III抑制剂来研究阿尔茨海默氏病
5. Structure-based design and synthesis of selective small molecule inhibitors for Mcl-1, an important cancer target [D] . McNulty, Oren 2015

机译：Mcl-1（一种重要的癌症靶标）的选择性小分子抑制剂的基于结构的设计和合成
6. Loss in MCL-1 function sensitizes non-Hodgkins lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199) [O] . D C Phillips, Y Xiao, L T Lam, 2016

机译：MCL-1功能的丧失使非霍奇金淋巴瘤细胞系对BCL-2选择性抑制剂Venetoclax（ABT-199）敏感
7. Erratum: Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199) [O] . D C Phillips, Y Xiao, L T Lam, 2016

机译：错误：MCL-1功能的损失使非Hodgkin的淋巴瘤细胞系致敏于Bcl-2选择性抑制剂venetoclax（ABT-199）

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号